Nucleic Acid Therapies and Biomaterial Delivery for Mpox: A Review of Possibilities and Limitations
Background: A review of viral inhibition and delivery technologies
Nucleic acid therapies targeting mpox virus (MPXV) have shown inhibitory potential in cell experiments, but delivery to infected sites and safety validation remain challenges. A review published in International Journal of Molecular Sciences examines RNA interference, gene editing, small-molecule antivirals, and other approaches, summarizing their potential and development challenges. It is a literature review of existing research and future strategies, rather than a report of a new clinical trial in patients or the efficacy of a single treatment.
MPXV replicates its genome and produces viral proteins in the cytoplasm. This underlies the investigation of approaches that suppress the expression of genes needed for viral multiplication or block proteins involved in replication and release. However, selecting a target and safely delivering a drug to infected sites are separate challenges. The review discusses the potential use of delivery technologies, including lipid and polymer nanoparticles, alongside nucleic acid therapies.
Key findings: In vitro RNA interference results and proposed CRISPR therapies
An RNA interference (RNAi) study cited in the review examined 12 conserved MPXV genes in mammalian cells. The researchers designed four small interfering RNAs (siRNAs) for each gene, for a total of 48. According to the review, siRNA pools targeting A6R and E8L reduced viral production by approximately 65–95%, with low observed cytotoxicity. The review also reports that the individual siRNA siA6-a maintained inhibitory activity for up to seven days after infection, even at a concentration of 10 nM.
These figures come from cell experiments. They do not indicate improved symptoms or reduced transmission in patients, and they are not results of new experiments conducted by the review authors. The findings cannot readily support claims of superiority over other treatments or predictions of effects in patients.
Evidence for diagnostic and therapeutic uses of CRISPR must be assessed separately. The review describes a diagnostic example combining Cas12a-based MPXV detection with amplification technology. By contrast, cutting essential viral genes or editing bases to reduce infectivity is proposed as a future therapeutic strategy. Successful viral detection is not evidence of safe viral elimination from infected cells.
Peptide nucleic acids (PNAs) and antisense oligonucleotides (ASOs) are also reviewed. These approaches aim to bind complementarily to specific viral RNA and interfere with the production of essential proteins; target-sequence selection and delivery are central to their development. The review also covers small molecules and neutralizing antibodies targeting proteins involved in viral replication and spread. Proposed approaches, cell experiments, and animal-study findings must be distinguished from clinical effects demonstrated in patients.
Significance and outlook: Connecting target inhibition to treatment
The development direction outlined in the review is to evaluate target-specific inhibitory approaches together with delivery vehicles. For example, lipid or polymer nanoparticles could be explored with RNAi candidates to improve nucleic acid stability and delivery to infected sites. However, this review alone cannot establish that a particular delivery vehicle has demonstrated efficacy in patients with MPXV infection.
In vivo application still faces challenges involving efficient delivery to skin lesions, avoidance of unwanted immune activation, duration of inhibition, and viral escape from targeting. Other treatment approaches also have limitations. The review identifies cidofovir-associated nephrotoxicity, safety concerns with brincidofovir, and the cost of antibody therapy as barriers to clinical use. Combination strategies addressing multiple targets are also discussed as possibilities, but their benefits and safety in patients require separate validation.
This review can help researchers identify targets and delivery technologies for follow-up experiments. Supporting evidence and detailed discussion are available in the full review.
Nature, Published online: 27 May 2026. DOI: 10.1038/s41586-026-10569-6
Summary: Challenging the historical free-radical dogma where reactive oxygen species-driven oxidative damage was defined as the absolute generator of mitochondrial genomic instability, this landmark population-scale study delineates the structural implementation of high-depth genome-wide analyses over multi-thousand blood cohorts. The deep molecular registry isolates that the accumulation of mitochondrial DNA mutations is programmatically driven by cryptic replication errors rather than environmental oxidation kinetics. These heritable sequence alterations operate initially as sub-clinical passenger mutations, which dynamically expand into high-penetrance arrays due to age-related somatic mosaicism. The data provides a non-oxidative computational baseline establishing DNA polymerase fidelity as the principal driver of transcriptomic aging, optimizing prospective interventions, and liquid biopsy stratification.
For researchers developing nucleic acid therapies, this review offers a starting point for connecting target selection with delivery-vehicle evaluation. For example, researchers could select follow-up candidates based on the in vitro inhibition results for siRNAs targeting A6R and E8L, then plan comparisons of how lipid or polymer carriers affect delivery to skin lesions, nucleic acid stability, immune activation, and duration of effect. This would evaluate delivery and safety alongside viral inhibition. However, the reported inhibition rates have not been validated as indicators of efficacy in patients or the likelihood of clinical success. CRISPR diagnostic findings must likewise be assessed separately from therapeutic potential, and this review provides insufficient grounds for changing treatment recommendations.